The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination-proteasome degradation pathway
Abstract
Induced protein degradation by PROTACs has emerged as a promising strategy to target nonenzymatic proteins inside the cell. The aim of this study was to identify Keap1, a substrate adaptor protein for ubiquitin E3 ligase involved in oxidative stress regulation, as a novel candidate for PROTACs that can be applied in the degradation of the nonenzymatic protein Tau. A peptide PROTAC by recruiting Keap1-Cul3 ubiquitin E3 ligase was developed and applied in the degradation of intracellular Tau. Peptide 1 showed strong in vitro binding with Keap1 and Tau. With proper cell permeability, peptide 1 was found to colocalize with cellular Keap1 and resulted in the coimmunoprecipitation of Tau and Keap1. The results of flow cytometry and western blotting assays showed that peptide 1 can downregulate the intracellular Tau level in both time- and concentration-dependent manner. The application of Keap1 siRNA silencing and the proteasome inhibitor MG132 confirmed that peptide 1 could promote the Keap1-dependent poly-ubiquitination and proteasome-dependent degradation of Tau. The results suggested that using PROTACs to recruit Keap1 to induce the degradation of Tau may show promising character in the treatment of neurodegenerative disease. Besides, our research demonstrated that Keap1 should be a promising E3 ligase adaptor to be used in the design of novel PROTACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, induced turnover of tau by the UPS, and the degradability of tau species, has been demonstrated by a tau–kelch-like ECH-associated protein 1 (KEAP1) chimeric peptide PROTAC molecule188, as well as by a VHL–tau PROTAC189.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“Additionally, multiple groups have described a range of pepTACs that harness SKP1/SCF F-box, VHL, KEAP1 and other E3 ligases to degrade tau or α-synuclein in primary neurons and other cell lines188,193,213”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [188]
In the citing paper
“A peptide-based PROTAC which recruits the KEAP1 E3 ligase to degrade Tau protein demonstrates the potential of PROTAC technology to treat neurodegenerative disorders such as Alzheimer’s disease [73].”
From PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics (2020) · cites this paper as [73]
In the citing paper
“This PROTAC, termed peptide 1, was able to degrade overexpressed GFP-tagged Tau in different cell lines at 20 µM after 6–12 h of treatment times to various degrees.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Recently, a peptide PROTAC was developed that was able to tether Kelch-like ECH-associated protein-1 (Keap1) and Tau into a ternary complex [105].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Generation of the full-length peptide decreased Keap1 affinity tenfold and exhibited affinity towards Tau in the sub-micromolar range.”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [105]
In the citing paper
“Proof of concept for hijacking the BTB E3 ligases has been provided by a peptide PROTAC targeting Tau for degradation by KEAP1 (ref. 79 ).”
From Targeted protein degradation: expanding the toolbox (2019) · cites this paper as [79]
Citations
Cites
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Classification of Intrinsically Disordered Regions and Proteins
van der Lee, R., Buljan, M., Lang, B., Weatheritt, R. J., Daughdrill, G. W., Dunker, A. K., Fuxreiter, M., Gough, J., Gsponer, J., Jones, D. T., et al. (2014) · Chemical Reviews · doi:10.1021/cr400525m · Cited by 2,249
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Hoover, B. R., Reed, M. N., Su, J., Penrod, R. D., Kotilinek, L. A., Grant, M. K., Pitstick, R., Carlson, G. A., Lanier, L. M., Yuan, L.-L., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.030 · Cited by 1,118
Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
Zengerle, M., Chan, K.-H., & Ciulli, A. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00216 · Cited by 1,056
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Lu, M., Ji, J., Jiang, Z., & You, Q. (2016) · Medicinal Research Reviews · doi:10.1002/med.21396 · Cited by 815
Self-citation
Research works printed but not linked: 1
- Lu, 2016, The Keap1–Nrf2–ARE pathway as a potential preventive and therapeutic target: an update, Med. Res. Rev., 36, 924, 10.1002/med.21396 · DOI
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Targeted protein degradation: mechanisms, strategies and application
Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 1,035
Targeted protein degradation: expanding the toolbox
Schapira, M., Calabrese, M. F., Bullock, A. N., & Crews, C. M. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0047-y · Cited by 960
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 830
An open-source drug discovery platform enables ultra-large virtual screens
Gorgulla, C., Boeszoermenyi, A., Wang, Z., Fischer, P. D., Coote, P. W., Das, K. M., Malets, Y. S., Radchenko, D. S., Moroz, Y. S., Scott, D. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2117-z · Cited by 677
PROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y.-G., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 663
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 598
Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Ossenkoppele, R., van der Kant, R., & Hansson, O. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(22)00168-5 · Cited by 557
Cotton, A. D., Nguyen, D. P., Gramespacher, J. A., Seiple, I. B., & Wells, J. A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c10008 · Cited by 551
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 523
Nrf2/Keap1/ARE signaling: Towards specific regulation
Ulasov, A. V., Rosenkranz, A. A., Georgiev, G. P., & Sobolev, A. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120111 · Cited by 534
Targeted protein degradation: from mechanisms to clinic
Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438
Current strategies for the design of PROTAC linkers: a critical review
Troup, R. I., Fallan, C., & Baud, M. G. J. (2020) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2020.00018 · Cited by 424
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Madden, S. K., de Araujo, A. D., Gerhardt, M., Fairlie, D. P., & Mason, J. M. (2021) · Molecular Cancer · doi:10.1186/s12943-020-01291-6 · Cited by 404
E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220965528 · Cited by 404
Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities
Schmidt, M. F., Gan, Z. Y., Komander, D., & Dewson, G. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-020-00706-7 · Cited by 379
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
Donovan, K. A., Ferguson, F. M., Bushman, J. W., Eleuteri, N. A., Bhunia, D., Ryu, S., Tan, L., Shi, K., Yue, H., Liu, X., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.038 · Cited by 359
An overview of PROTACs: a promising drug discovery paradigm
Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 380
Degradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Riching, K. M., Mahan, S. D., Corona, C. R., McDougall, M. G., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 310
The PROTAC technology in drug development
Zou, Y., Ma, D., & Wang, Y. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3369 · Cited by 312
Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 286
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Alabi, S. B., & Crews, C. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100647 · Cited by 279
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene · doi:10.1038/s41388-020-1336-y · Cited by 252
Wang, W., Zhou, Q., Jiang, T., Li, S., Ye, J., Zheng, J., Wang, X., Liu, Y., Deng, M., Ke, D., et al. (2021) · Theranostics · doi:10.7150/thno.55680 · Cited by 242
Self-citationRecent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 207
PROTACs to address the challenges facing small molecule inhibitors
Martín-Acosta, P., & Xiao, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112993 · Cited by 192
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery
Guedeney, N., Cornu, M., Schwalen, F., Kieffer, C., & Voisin‐Chiret, A. S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103395 · Cited by 180
E3 ligase ligand chemistries: from building blocks to protein degraders
Sosič, I., Bricelj, A., & Steinebach, C. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00148a · Cited by 176
PROTACs– a game-changing technology
Konstantinidou, M., Li, J., Zhang, B., Wang, Z., Shaabani, S., ter Brake, F., Essa, K., & Dömling, A. S. S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1659242 · Cited by 171
Limorenko, G., & Lashuel, H. A. (2021) · Chemical Society Reviews · doi:10.1039/d1cs00127b · Cited by 168
Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta
Bai, N., Miller, S. A., Andrianov, G. V., Yates, M., Kirubakaran, P., & Karanicolas, J. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c01451 · Cited by 157
Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation
Wei, J., Meng, F., Park, K.-S., Yim, H., Velez, J., Kumar, P., Wang, L., Xie, L., Chen, H., Shen, Y., et al. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c04841 · Cited by 154
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 152
The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination
Jin, J., Wu, Y., Chen, J., Shen, Y., Zhang, L., Zhang, H., Chen, L., Yuan, H., Chen, H., Zhang, W., et al. (2020) · Theranostics · doi:10.7150/thno.46985 · Cited by 148
Characteristic roadmap of linker governs the rational design of PROTACs
Dong, Y., Ma, T., Xu, T., Feng, Z., Li, Y., Song, L., Yao, X., Ashby, C. R., & Hao, G.-F. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.007 · Cited by 146
Niewiadomska, G., Niewiadomski, W., Steczkowska, M., & Gąsiorowska, A. (2021) · Life · doi:10.3390/life11010028 · Cited by 138
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra, M., Hekking, K. F. W., Hijfte, L. V., & Folmer, R. H. A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.01.006 · Cited by 125
Strategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 120
Tau Protein Squired by Molecular Chaperones During Alzheimer’s Disease
Gorantla, N. V., & Chinnathambi, S. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1174-3 · Cited by 113
Hu, M., Zhou, W., Wang, Y., Yao, D., Ye, T., Yao, Y., Chen, B., Liu, G., Yang, X., Wang, W., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.010 · Cited by 117
Delivering on the promise of protein degraders
O’Brien, M. N., Luthra, S. A., Brown, M. F., & Bartlett, D. W. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00652-2 · Cited by 109
Progress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins
Lin, J., Jin, J., Shen, Y., Zhang, L., Gong, G., Bian, H., Chen, H., Nagle, D. G., Wu, Y., Zhang, W., et al. (2021) · Theranostics · doi:10.7150/thno.62686 · Cited by 102
Exploring the target scope of KEAP1 E3 ligase-based PROTACs
Du, G., Jiang, J., Henning, N. J., Safaee, N., Koide, E., Nowak, R. P., Donovan, K. A., Yoon, H., You, I., Yue, H., et al. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.08.003 · Cited by 97
Advances in targeted degradation of endogenous proteins
Röth, S., Fulcher, L. J., & Sapkota, G. P. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03112-6 · Cited by 92
Wang, L., Bharti, Kumar, R., Pavlov, P. F., & Winblad, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112915 · Cited by 92
Targeting SLC transporters: small molecules as modulators and therapeutic opportunities
Schlessinger, A., Zatorski, N., Hutchinson, K., & Colas, C. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.05.011 · Cited by 93
Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 89
Tomoshige, S., & Ishikawa, M. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004746 · Cited by 88
Piperlongumine conjugates induce targeted protein degradation
Pei, J., Xiao, Y., Liu, X., Hu, W., Sobh, A., Yuan, Y., Zhou, S., Hua, N., Mackintosh, S. G., Zhang, X., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.01.004 · Cited by 87
Recent progress in Keap1-Nrf2 protein-protein interaction inhibitors
Mou, Y., Wen, S., Li, Y., Gao, X., Zhang, X., & Jiang, Z. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112532 · Cited by 85
Self-citationTargeting the Ubiquitin-Proteasome System for Cancer Therapeutics by Small-Molecule Inhibitors
LaPlante, G., & Zhang, W. (2021) · Cancers · doi:10.3390/cancers13123079 · Cited by 88
A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies
Zheng, J., Tian, N., Liu, F., Zhang, Y., Su, J., Gao, Y., Deng, M., Wei, L., Ye, J., Li, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00669-2 · Cited by 78
Recent Advances in PROTACs for Drug Targeted Protein Research
Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 79
Advancing Strategies for Proteolysis-Targeting Chimera Design
Li, M., Zhi, Y., Liu, B., & Yao, Q. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01555 · Cited by 78
Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs
Shah, R. R., Redmond, J. M., Mihut, A., Menon, M. R., Evans, J. P., Murphy, J. A., Bartholomew, M. A., & Coe, D. M. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115326 · Cited by 75
Bright and stable luminescent probes for target engagement profiling in live cells
Payne, N. C., Kalyakina, A. S., Singh, K., Tye, M. A., & Mazitschek, R. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00877-5 · Cited by 74
Heim, C., Pliatsika, D., Mousavizadeh, F., Bär, K., Alvarez, B. H., Giannis, A., & Hartmann, M. D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00454 · Cited by 75
Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders
Liu, X., Zhang, X., Lv, D., Yuan, Y., Zheng, G., & Zhou, D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0073 · Cited by 75
A novel cereblon modulator for targeted protein degradation
Kim, S. A., Go, A., Jo, S.-H., Park, S. J., Jeon, Y. U., Kim, J. E., Lee, H. K., Park, C. H., Lee, C.-O., Park, S. G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.023 · Cited by 72
Expanding the landscape of E3 ligases for targeted protein degradation
Kramer, L. T. S., & Zhang, X. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2022.100020 · Cited by 70
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Mostofian, B., Martin, H., Razavi, A. M., Patel, S., Allen, B. K., Sherman, W., & Izaguirre, J. A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00603 · Cited by 70
Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries
Wang, B., Liu, J., Tandon, I., Wu, S., Teng, P., Liao, J., & Tang, W. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113425 · Cited by 67
Small molecule PROTACs: an emerging technology for targeted therapy in drug discovery
Pei, H., Peng, Y., Zhao, Q., & Chen, Y. (2019) · RSC Advances · doi:10.1039/c9ra03423d · Cited by 70
Shagufta, Ahmad, I., Mathew, S., & Rahman, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00570f · Cited by 64
Mayuri, K., Sreeraman, S., Somala, C. S., Kushwah, R. B. S., Saravanan, K. M., Sundaram, V., & Anand, T. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0072 · Cited by 64
Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases
Hyun, S., & Shin, D. (2021) · Life · doi:10.3390/life11070607 · Cited by 68
Protein aggregation and its affecting mechanisms in neurodegenerative diseases
Wu, J., Wu, J., Chen, T., Cai, J., & Ren, R. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105880 · Cited by 62
Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery
Madden, S. K., & Itzhaki, L. S. (2020) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2020.140405 · Cited by 62
Discovery of a PROTAC targeting ALK with in vivo activity
Yan, G., Zhong, X.-X., Lin, Y., Pu, C., Shan, H., Lan, S., Zhou, M., Hou, X., Yang, J., & Li, R. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113150 · Cited by 59
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Huang, X., Wu, F., Ye, J., Wang, L., Wang, X., Li, X., & He, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.010 · Cited by 62
Non-small molecule PROTACs (NSM-PROTACs): Protein degradation kaleidoscope
Ma, S., Ji, J., Tong, Y., Zhu, Y., Dou, J., Zhang, X., Xu, S., Zhu, T., Xu, X., You, Q., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.02.022 · Cited by 59
Self-citationCurrent advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 58
Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier
Tashima, T. (2023) · Antibodies · doi:10.3390/antib12030043 · Cited by 58
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 55
Applications of Bacterial Degrons and Degraders — Toward Targeted Protein Degradation in Bacteria
Izert, M. A., Klimecka, M. M., & Górna, M. W. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.669762 · Cited by 50
Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates
Zhu, W., Zhang, W., Chen, J., Tong, Y., Xu, F., & Pang, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01719 · Cited by 54
PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A.-H. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0001 · Cited by 54
Mei, L., Chen, X., Wei, F., Huang, X. S., Liu, L., Yao, J., Chen, J., Luo, X., Wang, Z., & Yang, A. (2023) · Autophagy · doi:10.1080/15548627.2023.2234797 · Cited by 50
Nature's toolbox against tau aggregation: An updated review of current research
Khan, S., Hassan, M. I., Shahid, M., & Islam, A. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101924 · Cited by 50
Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies
Kumar, D., Ambasta, R. K., & Kumar, P. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101078 · Cited by 51
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
Zhang, Z., Chang, X., Zhang, C., Zeng, S., Liang, M., Ma, Z., Wang, Z., Huang, W., & Shen, Z. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1804382 · Cited by 46
Valeur, E., & Jimonet, P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00378 · Cited by 43
Targeted protein degradation mechanisms
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.001 · Cited by 44
Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon, S., & Lee, B. (2018) · Europe PMC (PubMed Central) · doi:10.14348/molcells.2018.0372 · Cited by 47
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 45
Targeted Protein Degradation to Overcome Resistance in Cancer Therapies: PROTAC and N-Degron Pathway
Kim, H., Park, J., & Kim, J. (2022) · Biomedicines · doi:10.3390/biomedicines10092100 · Cited by 45
Tau degradation in Alzheimer's disease: Mechanisms and therapeutic opportunities
Wang, L., Banesh, S., Kumar, R., Schedin‐Weiss, S., Tjernberg, L. O., & Winblad, B. G. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70048 · Cited by 47
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 48
Yao, D., Li, T., Yu, L., Hu, M., He, Y., Zhang, R., Wu, J., Li, S., Kuang, W., Yang, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1351792 · Cited by 46
PROTACS: A technology with a gold rush-like atmosphere
Wang, Y., Lan, L., Wang, M., Zhang, J., Gao, Y., Shi, L., & Sun, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115037 · Cited by 44
Progress in the controllability technology of PROTAC
He, X. W., Weng, Z., & Zou, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116096 · Cited by 42
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 61
Metadata
- Authors
- Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- You, Qidong
- Jiang, Zhengyu
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 146
- Pages
- 251-259
- ISSN
- 0223-5234 (ISSN-L)
- OpenAlex
- W2792069216
- Cited by
- 310
- References
- 45
- Citations by year
- 2026: 30 · 2025: 46 · 2024: 48 · 2023: 47 · 2022: 35 · 2021: 36 · 2020: 37 · 2019: 24 · 2018: 6
- FWCI
- 9.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81773581, 81602948, 81773639)
- Natural Science Foundation of Jiangsu Province of China (BK20160746)
- National Major Science and Technology Project of China (2015ZX09101032, 2017ZX09302003, 2017ZX09101-004-003-006)
- Research Innovation Program for College Graduates of Jiangsu Province (KYLX16_1169)
- Priority Academic Program Development of Jiangsu Higher Education Institutions, the Project Program of State Key Laboratory of Natural Medicines, China Pharmaceutical University (SKLNMZZCX201611)
- College Students Innovation Project for the R&D of Novel Drugs (J1310032)
- China Postdoctoral Science Foundation funded project (1600010006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, Keap1, tau protein, ubiquitination, proteasomal degradation, protein degradation, neurodegenerative diseases, polyubiquitination
- MeSH terms
- Kelch-Like ECH-Associated Protein 1, Dose-Response Relationship, Drug, Humans, Peptides, Structure-Activity Relationship, Tumor Cells, Cultured, Molecular Structure, tau Proteins, Proteasome Endopeptidase Complex, Ubiquitination, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
